Introduction:
The market for value-based contracting in the cell and gene therapy (CGT) industry is rapidly evolving, with more companies and countries embracing this innovative approach. According to industry experts, the global market for CGT is expected to reach $10.2 billion by 2026, driven by increasing demand for personalized and targeted therapies.
Unveil Top 30 Premier Value-Based Contracting Success Stories in CGT 2026:
1. Novartis AG: Leading the way in value-based contracting with its groundbreaking CGT therapies, including Kymriah and Zolgensma. Novartis has secured numerous value-based agreements with payers to ensure patient access to these life-saving treatments.
2. Gilead Sciences: Known for its innovative CGT pipeline, Gilead Sciences has successfully implemented value-based contracts for its CAR-T therapy Yescarta. The company continues to expand its reach in the CGT market.
3. Roche Holdings: Roche has established itself as a key player in value-based contracting for CGT, particularly with its hemophilia gene therapy Hemlibra. The company’s commitment to patient outcomes has set a new standard in the industry.
Insights:
The increasing adoption of value-based contracting in the CGT industry reflects a shift towards a more patient-centric approach. Companies that prioritize outcomes and value are likely to see greater success in the market. As the industry continues to grow, collaboration between stakeholders will be key to driving innovation and improving patient access to life-changing therapies. By embracing value-based contracting, companies can not only improve patient outcomes but also ensure sustainable growth in the evolving CGT market.
Related Analysis: View Previous Industry Report
